Agios to Participate in March Investor Conferences

Rhea-AI Summary

Agios Pharmaceuticals (NASDAQ: AGIO) has announced its participation in major investor conferences scheduled for March 2022, specifically the Cowen 42nd Annual Virtual Healthcare Conference on March 7, 2022, and the Oppenheimer 32nd Annual Virtual Healthcare Conference on March 16, 2022. The live presentations will be accessible via the company’s website, and replays will be available for two weeks after each event. Agios specializes in therapies for genetically defined diseases, including a first-in-class treatment for PK deficiency.

CAMBRIDGE, Mass., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism pioneering therapies for genetically defined diseases, today announced the company is scheduled to present at the following March investor conferences:

• Cowen 42^nd Annual Virtual Healthcare Conference on Monday, March 7, 2022, at 9:10 a.m. ET; and
• Oppenheimer 32^nd Annual Virtual Healthcare Conference on Wednesday, March 16, 2021 at 1:20 p.m. ET.

Live webcasts of the presentations can be accessed under "Events & Presentations" in the Investors section of the company's website at www.agios.com. Replays of the webcasts will be archived on the Agios website for at least two weeks following each presentation.

About Agios
Agios is a biopharmaceutical company that is fueled by connections. The Agios team cultivates strong bonds with patient communities, healthcare professionals, partners and colleagues to discover, develop and deliver therapies for genetically defined diseases. In the U.S., Agios markets a first-in-class pyruvate kinase (PK) activator for adults with PK deficiency, the first disease-modifying therapy for this rare, lifelong, debilitating hemolytic anemia. Building on the company's leadership in the field of cellular metabolism, Agios is advancing a robust clinical pipeline of investigational medicines with active and planned programs in alpha- and beta-thalassemia, sickle cell disease, pediatric PK deficiency and MDS-associated anemia. In addition to its clinical pipeline, Agios has multiple investigational therapies in preclinical development and an industry-leading research team with unmatched expertise in cellular metabolism and genetics. For more information, please visit the company’s website at www.agios.com.

Contacts

Investors:
Holly Manning, 617-844-6630
Senior Director, Investor Relations
Holly.Manning@agios.com

Media:
Jessica Rennekamp, 857-209-3286
Director, Corporate Communications
Jessica.Rennekamp@agios.com 

FAQ

What is the schedule for Agios Pharmaceuticals' investor presentations in March 2022?

Agios Pharmaceuticals will present at the Cowen 42nd Annual Virtual Healthcare Conference on March 7, 2022, at 9:10 a.m. ET, and at the Oppenheimer 32nd Annual Virtual Healthcare Conference on March 16, 2022, at 1:20 p.m. ET.

How can I view the Agios Pharmaceuticals conference presentations?

The live webcasts of the Agios Pharmaceuticals presentations can be accessed in the 'Events & Presentations' section of their website, with replays archived for at least two weeks after each presentation.

What is Agios Pharmaceuticals known for?

Agios Pharmaceuticals is known for pioneering therapies for genetically defined diseases and markets a first-in-class pyruvate kinase activator for adults with PK deficiency.

What types of diseases does Agios Pharmaceuticals focus on?

Agios Pharmaceuticals focuses on therapies for genetically defined diseases, including alpha- and beta-thalassemia, sickle cell disease, and MDS-associated anemia.

What is the ticker symbol for Agios Pharmaceuticals?

The ticker symbol for Agios Pharmaceuticals is AGIO.